Reese Terry, Founder and Former CEO of Cyberonics, Joins ElectroCore Board of Directors
MORRIS PLAINS, N.J., Jan. 4, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious headache conditions and bronchoconstriction, announced today that Reese Terry, co-founder and former CEO of Cyberonics, Inc., has joined its Board of Directors.
Mr. Terry brings more than 25 years of relevant medical device industry experience to ElectroCore. He co-founded Cyberonics in 1987 to develop, manufacture and market neuromodulation therapies for patients with epilepsy and other inadequately treated neurological disorders. The company received FDA approval for use of its implantable vagal nerve stimulators (VNS) for the treatment of refractory epilepsy in 1997 and in patients with treatment-resistant depression in 2005. Since its founding, more than 67,000 patients worldwide have been implanted with Cyberonics' VNS.
"We are honored to have someone with Reese's experience in the field of vagal stimulation join our Board of Directors," said JP Errico, CEO of ElectroCore. "Reese is a true pioneer in medicine, having introduced the world to the power of VNS nearly 25 years ago. His expertise and guidance will be invaluable, as we advance his vision of evolving technology from implantable to non-invasive, and move into new areas of medicine, including primary headache and bronchoconstriction."
Mr. Terry served as the CEO of Cyberonics from 1987 until 1991, and as interim CEO during parts of 1995, 2006 and 2007. He was a member of the Cyberonics' Board of Directors from 1987 through 2010. Prior to Cyberonics, Mr. Terry worked for medical device and electronics company Intermedics, Inc., where he served as Vice President of Engineering, Vice President of Corporate Technical Resources and Vice President of Quality. He began his career at Cordis Corporation, a heart pacemaker manufacturing company.
"ElectroCore is developing pioneering non-invasive therapies that deliver meaningful relief to patients in a safe, painless and convenient manner," said Mr. Terry. "I'm excited to draw upon my industry experience and become part of a team of experts who are working to revolutionize patient care."
ElectroCore is a healthcare company focused on non-invasive neuromodulation therapies for the treatment of diseases and disorders. The company has developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to treat and/or prevent symptoms of a number of highly prevalent and disabling conditions. ElectroCore currently has three commercial products on the market: GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia.
For more information, visit: http://www.electrocoremedical.com/.